{
    "eid": "2-s2.0-85139171097",
    "title": "Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B",
    "cover-date": "2022-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hepatology",
            "@code": "2721",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Man Fung Yuen",
        "Elina Berliba",
        "Wattana Sukeepaisarnjaroen",
        "Sang Hoon Ahn",
        "Tawesak Tanwandee",
        "Young Suk Lim",
        "Yoon Jun Kim",
        "Kittiyod Poovorawan",
        "Pisit Tangkijvanich",
        "Christian Schwabe",
        "Timothy Eley",
        "Joanne Brown",
        "Amy C.H. Lee",
        "Emily P. Thi",
        "Bhavna Paratala",
        "Nagraj Mani",
        "Michael J. Sofia",
        "Gaston Picchio",
        "Karen D. Sims",
        "Edward J. Gane"
    ],
    "citedby-count": 5,
    "ref-count": 34,
    "ref-list": [
        "Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD",
        "The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017",
        "Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013",
        "Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance",
        "EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection",
        "Modulators of HBV capsid assembly as an approach to treating hepatitis B virus infection",
        "Molecular biology of hepatitis B virus infection",
        "Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids",
        "HBc binds to the CpG islands of HBV cccDNA and promotes an epigenetic permissive state",
        "Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection",
        "JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a Phase 1 study of patients with chronic infection",
        "Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled Phase 1 trial",
        "A first-in-human trial of GLS4, a novel inhibitor of hepatitis B virus capsid assembly, following single- and multiple-ascending-oral-dose studies with or without ritonavir in healthy adult volunteers",
        "Single dose safety, tolerability and pharmacokinetics of AB-423 in healthy volunteers from the ongoing single and multiple ascending dose study AB-423-001",
        "RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients",
        "AASLD guidelines for treatment of chronic hepatitis B",
        "Serum HBV RNA as a predictor of peginterferon alfa-2a response in patients with HBeAg-positive chronic hepatitis B",
        "HBVdb: a knowledge database for Hepatitis B Virus",
        "Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data",
        "Virology analysis of chronic hepatitis B virus-infected patients treated for 28 days with JNJ-56136379 monotherapy",
        "Resistance monitoring data from treatment-naive chronic HBV infected patients treated for 28 days with a new class a core protein allosteric modulator RO7049389 monotherapy",
        "Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management",
        "Liver safety assessment in clinical trials of new agents for chronic hepatitis B",
        "Guidance for design and endpoints of clinical trials in chronic hepatitis B\u2014report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference",
        "Understanding idiosyncratic toxicity: lessons learned from drug-induced liver injury",
        "Phase 1a safety and pharmacokinetics of NVR 3-778, a potential first-in-class HBV core inhibitor",
        "RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBV activity in chronic hepatitis B patients and is safe and well tolerated",
        "Pharmacokinetics, safety and tolerability of JNJ-56136379, a novel hepatitis B virus capsid assembly modulator, in healthy subjects",
        "Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: results from 152 marketed drugs with known liver injury profiles"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60199575",
            "affilname": "Siriraj Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Seoul",
            "@id": "60095571",
            "affilname": "Severance Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60095571",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Seoul",
            "@id": "60068691",
            "affilname": "Asan Medical Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60068691",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Seoul",
            "@id": "60021119",
            "affilname": "Seoul National University Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021119",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60019543",
            "affilname": "Hospital for Tropical Diseases, Bangkok",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60019543",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Khon Kaen",
            "@id": "60017165",
            "affilname": "Khon Kaen University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017165",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Hong Kong",
            "@id": "60006541",
            "affilname": "The University of Hong Kong",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006541",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Auckland",
            "@id": "60005686",
            "affilname": "The University of Auckland",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60005686",
            "affiliation-country": "New Zealand"
        },
        {
            "affiliation-city": "Warminster",
            "@id": "128660555",
            "affilname": "Discovery",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/128660555",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Warminster",
            "@id": "128659936",
            "affilname": "Clinical Development",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/128659936",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Chisinau",
            "@id": "121353818",
            "affilname": "F.C.E. ARENSIA Exploratory Medicine LLC",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/121353818",
            "affiliation-country": "Moldova"
        },
        {
            "affiliation-city": "Auckland",
            "@id": "108297220",
            "affilname": "Brain Research New Zealand",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/108297220",
            "affiliation-country": "New Zealand"
        }
    ],
    "funding": [
        "Arbutus Biopharma, Inc.",
        "PharStat Inc."
    ]
}